You are here

STTR Phase I: Advanced Microfluidic Devices for Point-of-Care COVID-19 Serological Testing

Award Information
Agency: National Science Foundation
Branch: N/A
Contract: 2032222
Agency Tracking Number: 2032222
Amount: $256,000.00
Phase: Phase I
Program: STTR
Solicitation Topic Code: BM
Solicitation Number: N/A
Solicitation Year: 2020
Award Year: 2020
Award Start Date (Proposal Award Date): 2020-09-15
Award End Date (Contract End Date): 2021-08-31
Small Business Information
2401 Research Blvd. STE 107
Fort Collins, CO 80526
United States
DUNS: 078845198
HUBZone Owned: Yes
Woman Owned: No
Socially and Economically Disadvantaged: No
Principal Investigator
 Thomas Reilly
 (970) 818-7520
Business Contact
 Thomas Reilly
Phone: (970) 818-7520
Research Institution
 Colorado State University
 Brian J Geiss
601 S Howes St
Fort Collins, CO 80523
United States

 Nonprofit College or University

The broader impact/commercial potential of this Small Business Technology Transfer (STTR) Phase I project may reach millions of people and provide a key tool in safeguarding the public health through the COVID-19 pandemic. Sensitive, selective and quantitative detection usually requires complex laboratory-based methods and instrumentation to achieve consistent results; however, this project advances technologies to simplify the process. Antibody testing provides information regarding previous infections; a simple tool to detect presence at low concentrations enables better testing to manage social distancing needs. The proposed technology aims to make blood testing for SARS-Cov-2 simple and quantitative for two types of antibodies. The device will be developed to take patient samples directly with no complicated sample prep. Unique reagents will be created for selective detection of the SARS-CoV-2 antibodies. This Small Business Technology Transfer (STTR) Phase I project aims to develop the next generation of low-cost point of care immunoassay technology with direct application to infectious disease detection. The technology proposed here combines a new approach to controlling capillary flow driven systems applied to the steps of a traditional ELISA in a disposable device. The device developed in this project will detect SARSCoV-2 specific antibodies in patient samples, and will be able to provide information about the phase of the immune response of a patient. Additionally, adaption of ELISA-like enzymatic amplification into a point-of-care device will provide greater sensitivity and selectivity than traditional lateral flow assays, increasing assay sensitivity and improving detection of early infections. The immunoassays will be evaluated with deidentified patient samples and compared to state of the art laboratory-based detection methods. This award reflects NSF's statutory mission and has been deemed worthy of support through evaluation using the Foundation's intellectual merit and broader impacts review criteria.

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government